Breakthrough: Roche's New Hemophilia Drug Achieves Zero Bleeds in Clinical Trial, Challenges Market Leader

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout...

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated in adults and adolescents with hemophilia A, with or without inhibitors1FRONTIER5 Patient-Reported Outcomes assessment found the…

Breakthrough: Roche's New Hemophilia Drug Achieves Zero Bleeds in Clinical Trial, Challenges Market Leader

Early trial data reveals NXT007 achieved complete bleed prevention in highest dose groups. Phase III head-to-head study vs Hemlibra planned for 2026. See full results.